TSFECG03:	Categorized Change From Baseline to Maximum On-treatment Corrected QT Interval; Safety Analysis Set (Study jjcs - core)				
 	Active Study Agent 	Active Study Agent 	 	
QTc Interval 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
   Criteria, n (%) 	N=53 	N=73 	N=59 	
QTcB Interval, Aggregate (msec) 	 	 	 	
N 	53 	53 	56 	
≤30 	30 (56.6%) 	29 (54.7%) 	37 (66.1%) 	
>30 to ≤60 	5 (9.4%) 	3 (5.7%) 	2 (3.6%) 	
>60 	18 (34.0%) 	21 (39.6%) 	17 (30.4%) 	
 	 	 	 	
QTcF Interval, Aggregate (msec) 	 	 	 	
N 	53 	53 	56 	
≤30 	31 (58.5%) 	25 (47.2%) 	28 (50.0%) 	
>30 to ≤60 	4 (7.5%) 	3 (5.7%) 	8 (14.3%) 	
>60 	18 (34.0%) 	25 (47.2%) 	20 (35.7%) 	

Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation. 	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: N is the number of subjects with at least 1 non-missing change from baseline value for the ECG parameter over the specified time period. 	: N is the number of subjects with at least 1 non-missing change from baseline value for the ECG parameter over the specified time period.	: N is the number of subjects with at least 1 non-missing change from baseline value for the ECG parameter over the specified time period.	: N is the number of subjects with at least 1 non-missing change from baseline value for the ECG parameter over the specified time period.